South Street Advisors LLC Reduces Position in Novo Nordisk A/S $NVO

South Street Advisors LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 61.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,537 shares of the company’s stock after selling 38,829 shares during the quarter. South Street Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,362,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Revolve Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the period. AQR Capital Management LLC increased its stake in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the last quarter. Savant Capital LLC lifted its position in shares of Novo Nordisk A/S by 3.0% during the second quarter. Savant Capital LLC now owns 13,932 shares of the company’s stock worth $962,000 after purchasing an additional 403 shares during the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Novo Nordisk A/S by 9.0% during the second quarter. SBI Securities Co. Ltd. now owns 14,336 shares of the company’s stock valued at $989,000 after purchasing an additional 1,186 shares during the period. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NVO. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a report on Tuesday, March 3rd. Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Four research analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $49.93.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $37.99 on Friday. The firm has a 50 day moving average of $50.14 and a 200 day moving average of $51.79. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $169.61 billion, a price-to-earnings ratio of 10.95 and a beta of 0.73. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.